Cargando…
Effect of Dolutegravir on Plasma Glucose Among Human Immunodeficiency Virus Patients in a Community Health Center Setting
Background Dolutegravir has become one of the initial backbones in antiretroviral therapy regimens for most patients with HIV in several recent clinical guidelines. However, dolutegravir has been associated with severe cases of hyperglycemia and the new-onset of diabetes in multiple case reports and...
Autor principal: | Bahamdain, Foud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586418/ https://www.ncbi.nlm.nih.gov/pubmed/36303801 http://dx.doi.org/10.7759/cureus.30556 |
Ejemplares similares
-
Graves’ Disease in a Patient With Human Immunodeficiency Virus Infection as an Immune Reconstitution Inflammatory Syndrome
por: Ayad, Sarah, et al.
Publicado: (2021) -
Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus
por: Nimitphong, Hataikarn, et al.
Publicado: (2022) -
Spectrum of Dyslipidemias in Treatment-Naïve Human Immunodeficiency Virus-Infected Patients Presenting to an HIV Clinic of a Tertiary Care Hospital
por: Iqbal, Sadaf, et al.
Publicado: (2022) -
Relationship Between Estimated Average Glucose (eAG) and Fasting Plasma Glucose in a Cohort of Pakistani Diabetic Subjects
por: Ram, Nanik, et al.
Publicado: (2021) -
Changes in β-Cell Function in Offspring of Type-2 Diabetic Patients, as per Fasting and Two-Hour Plasma Glucose Levels
por: Praveen, Edavan Pulikkanath, et al.
Publicado: (2021)